



[Home](#) / [Investors](#) / [News Releases](#)

# Insmed to Discuss Litigation Settlement with Tercica

RICHMOND, Va., Mar 06, 2007 (BUSINESS WIRE) -- Insmed (NASDAQ:INSM) announced that it will host a conference call on Wednesday, March 7 at 11:00 a.m. (ET) to discuss the litigation settlement with Genentech and Tercica, and other business details.

Among participants on the call will be Geoffrey Allan, Ph.D., president and CEO of Insmed and Kevin Tully, Executive Vice President and CFO.

Interested investors can listen to the call over the Internet from Insmed's investor relations website at [www.insmed.com](http://www.insmed.com) or by dialing (888) 802-2225 (domestic) or (913) 312-1268 (international).

A telephonic replay of the call will be available for two weeks, by dialling (888) 203-1112 (domestic) or (719) 457-0820 (international). The passcode # is 4396908.

A web replay of the call will be available through the corporate website.

## About Insmed

Insmed Inc. is a biopharmaceutical company focused on the development and commercialization of drug candidates for the treatment of metabolic diseases and endocrine disorders with unmet medical needs. For more information, please visit [www.insmed.com](http://www.insmed.com)

## Insmed Safe Harbor Statement

Statements included within this press release, which are not historical in nature, may constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include, but are not limited to, statements regarding business strategies, growth opportunities for approved or proposed products, plans and objectives of management. Such forward-looking statements are subject to numerous risks and uncertainties, including risks that our product candidates may fail in clinical trials or may not be successfully marketed, we may lack financial resources to complete development of product candidates, we may be unable to raise additional financing necessary to continue current operations competing products may be more successful, demand for new pharmaceutical products may decrease and the biopharmaceutical industry may experience negative market trends. As a result of these and other risks and uncertainties, actual results may differ materially from those described in this press release. For further information with respect to factors that could cause actual results to differ from expectations, reference is made to reports filed by the Company with the Securities and Exchange Commission under the Securities Exchange Act of 1934, as amended. The forward-looking statements made in this release are made only as of the date hereof and Insmed disclaims any intention or responsibility for updating predictions or financial guidance contained in this release.

---